vs
Side-by-side financial comparison of Foghorn Therapeutics Inc. (FHTX) and NextPlat Corp (NXPL). Click either name above to swap in a different company.
NextPlat Corp is the larger business by last-quarter revenue ($12.8M vs $9.2M, roughly 1.4× Foghorn Therapeutics Inc.). NextPlat Corp runs the higher net margin — -40.2% vs -234.3%, a 194.1% gap on every dollar of revenue. On growth, Foghorn Therapeutics Inc. posted the faster year-over-year revenue change (223.8% vs -21.1%). Over the past eight quarters, Foghorn Therapeutics Inc.'s revenue compounded faster (35.3% CAGR vs -14.4%).
Foghorn Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing novel therapies targeting the chromatin regulatory system to treat various types of cancer and other severe diseases. It advances a diverse pipeline of targeted drug candidates, conducting internal R&D and strategic partnerships to serve global patient populations.
FHTX vs NXPL — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $9.2M | $12.8M |
| Net Profit | $-21.7M | $-5.1M |
| Gross Margin | — | 14.3% |
| Operating Margin | -258.2% | -28.9% |
| Net Margin | -234.3% | -40.2% |
| Revenue YoY | 223.8% | -21.1% |
| Net Profit YoY | -11.1% | -70.6% |
| EPS (diluted) | $-0.35 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $9.2M | $12.8M | ||
| Q3 25 | $8.2M | $13.8M | ||
| Q2 25 | $7.6M | $13.2M | ||
| Q1 25 | $6.0M | $14.5M | ||
| Q4 24 | $2.9M | $16.2M | ||
| Q3 24 | $7.8M | $15.4M | ||
| Q2 24 | $6.9M | $17.0M | ||
| Q1 24 | $5.0M | $17.5M |
| Q4 25 | $-21.7M | $-5.1M | ||
| Q3 25 | $-15.8M | $-2.2M | ||
| Q2 25 | $-17.9M | $-1.8M | ||
| Q1 25 | $-18.8M | $-1.3M | ||
| Q4 24 | $-19.5M | $-3.0M | ||
| Q3 24 | $-19.1M | $-4.2M | ||
| Q2 24 | $-23.0M | $-5.3M | ||
| Q1 24 | $-25.0M | $-1.5M |
| Q4 25 | — | 14.3% | ||
| Q3 25 | — | 19.9% | ||
| Q2 25 | — | 21.8% | ||
| Q1 25 | — | 23.8% | ||
| Q4 24 | — | 16.8% | ||
| Q3 24 | — | 23.2% | ||
| Q2 24 | — | 34.5% | ||
| Q1 24 | — | 27.8% |
| Q4 25 | -258.2% | -28.9% | ||
| Q3 25 | -226.9% | -14.5% | ||
| Q2 25 | -279.2% | -13.8% | ||
| Q1 25 | -385.0% | -10.2% | ||
| Q4 24 | -840.5% | -14.1% | ||
| Q3 24 | -305.5% | -52.1% | ||
| Q2 24 | -386.6% | -64.1% | ||
| Q1 24 | -558.3% | -10.5% |
| Q4 25 | -234.3% | -40.2% | ||
| Q3 25 | -194.4% | -15.9% | ||
| Q2 25 | -237.3% | -13.5% | ||
| Q1 25 | -316.4% | -9.2% | ||
| Q4 24 | -682.9% | -18.6% | ||
| Q3 24 | -244.9% | -27.4% | ||
| Q2 24 | -333.6% | -31.3% | ||
| Q1 24 | -495.4% | -8.5% |
| Q4 25 | $-0.35 | — | ||
| Q3 25 | $-0.25 | — | ||
| Q2 25 | $-0.28 | — | ||
| Q1 25 | $-0.30 | $-0.05 | ||
| Q4 24 | $-0.23 | — | ||
| Q3 24 | $-0.31 | $-0.22 | ||
| Q2 24 | $-0.45 | — | ||
| Q1 24 | $-0.59 | $-0.08 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $80.9M | $13.7M |
| Total DebtLower is stronger | — | $1.3M |
| Stockholders' EquityBook value | $-108.5M | $17.3M |
| Total Assets | $198.1M | $27.5M |
| Debt / EquityLower = less leverage | — | 0.07× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $80.9M | $13.7M | ||
| Q3 25 | $89.3M | $13.9M | ||
| Q2 25 | $72.6M | $16.6M | ||
| Q1 25 | $61.0M | $17.7M | ||
| Q4 24 | $55.5M | $20.0M | ||
| Q3 24 | $57.7M | $20.4M | ||
| Q2 24 | $138.9M | $24.9M | ||
| Q1 24 | $79.3M | $23.5M |
| Q4 25 | — | $1.3M | ||
| Q3 25 | — | $1.2M | ||
| Q2 25 | — | $1.2M | ||
| Q1 25 | — | $1.3M | ||
| Q4 24 | — | $1.4M | ||
| Q3 24 | — | $1.5M | ||
| Q2 24 | — | $1.3M | ||
| Q1 24 | — | $1.4M |
| Q4 25 | $-108.5M | $17.3M | ||
| Q3 25 | $-89.7M | $21.4M | ||
| Q2 25 | $-76.7M | $23.5M | ||
| Q1 25 | $-61.7M | $25.3M | ||
| Q4 24 | $-45.5M | $27.3M | ||
| Q3 24 | $-28.3M | $22.5M | ||
| Q2 24 | $-14.3M | $26.5M | ||
| Q1 24 | $-97.5M | $31.2M |
| Q4 25 | $198.1M | $27.5M | ||
| Q3 25 | $205.0M | $30.0M | ||
| Q2 25 | $226.2M | $31.0M | ||
| Q1 25 | $258.7M | $35.2M | ||
| Q4 24 | $284.0M | $37.1M | ||
| Q3 24 | $308.4M | $41.1M | ||
| Q2 24 | $328.6M | $51.5M | ||
| Q1 24 | $255.0M | $65.1M |
| Q4 25 | — | 0.07× | ||
| Q3 25 | — | 0.05× | ||
| Q2 25 | — | 0.05× | ||
| Q1 25 | — | 0.05× | ||
| Q4 24 | — | 0.05× | ||
| Q3 24 | — | 0.07× | ||
| Q2 24 | — | 0.05× | ||
| Q1 24 | — | 0.04× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-22.3M | $-302.0K |
| Free Cash FlowOCF − Capex | — | $-339.0K |
| FCF MarginFCF / Revenue | — | -2.6% |
| Capex IntensityCapex / Revenue | 0.0% | 0.3% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-22.3M | $-302.0K | ||
| Q3 25 | $-18.9M | $-2.7M | ||
| Q2 25 | $-21.0M | $-1.0M | ||
| Q1 25 | $-24.0M | $-2.1M | ||
| Q4 24 | $-24.5M | $-476.0K | ||
| Q3 24 | $-21.0M | $-4.6M | ||
| Q2 24 | $-25.5M | $2.3M | ||
| Q1 24 | $-29.3M | $-2.7M |
| Q4 25 | — | $-339.0K | ||
| Q3 25 | — | — | ||
| Q2 25 | $-21.0M | $-1.1M | ||
| Q1 25 | $-24.0M | $-2.1M | ||
| Q4 24 | $-25.0M | $-508.0K | ||
| Q3 24 | $-21.3M | $-4.7M | ||
| Q2 24 | $-25.6M | $2.2M | ||
| Q1 24 | $-29.4M | $-2.7M |
| Q4 25 | — | -2.6% | ||
| Q3 25 | — | — | ||
| Q2 25 | -278.2% | -8.0% | ||
| Q1 25 | -403.2% | -14.3% | ||
| Q4 24 | -875.3% | -3.1% | ||
| Q3 24 | -273.0% | -30.6% | ||
| Q2 24 | -371.0% | 13.2% | ||
| Q1 24 | -583.1% | -15.7% |
| Q4 25 | 0.0% | 0.3% | ||
| Q3 25 | 0.0% | 0.0% | ||
| Q2 25 | 0.3% | 0.1% | ||
| Q1 25 | 0.5% | 0.2% | ||
| Q4 24 | 16.8% | 0.2% | ||
| Q3 24 | 4.0% | 0.6% | ||
| Q2 24 | 0.2% | 0.4% | ||
| Q1 24 | 2.0% | 0.4% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
FHTX
Segment breakdown not available.
NXPL
| Healthcare Operations | $9.0M | 70% |
| Ecommerce Revenue | $3.8M | 30% |
